INGELHEIM, Germany. - Monday, August 25th 2014
HOT LINE: New results from RE-LY® compare the effect of warfarin and Pradaxa® on kidney function in patients requiring anticoagulation
HOT LINE: GLORIA™-AF Registry Program benchmarks patient characteristics and antithrombotic use for stroke prevention in AF worldwide
For Non-US/Non-UK/Non-Canadian Media
New Pradaxa® (dabigatran etexilate) data for the treatment of a broad range of thromboembolic diseases will be presented at the ESC Congress 2014, 30th August – 3rd September, 2014, Barcelona, Spain, organised by the European Society of Cardiology. Study results, including data being presented in two Hot Line sessions, will provide further clinical insights for Pradaxa® and help inform future anticoagulation treatment decisions.
On August 31st, the Registry Hot Line session will reveal data from the first 10,000 patients included in the GLORIA™-AF Registry Program, which will provide insights into patterns of antithrombotic treatment use for stroke prevention in atrial fibrillation (AF).
On September 2nd, a Clinical Trial Update Hot Line session will announce new data from a RE-LY® sub-analysis comparing the effects of warfarin and Pradaxa® on kidney function in AF patients requiring anticoagulation.
Further new data sets from company-sponsored studies involving Pradaxa® in AF, deep vein thrombosis and pulmonary embolism will also feature as poster and oral presentations during the ESC Congress 2014.
Abstracts are available from the ESC website at: http://spo.escardio.org/default.aspx?eevtid=69
In Barcelona, five years ago, the landmark RE-LY® study results were presented at the ESC Congress 2009. Since then, the RE-LY® findings have been reconfirmed in numerous sub-analyses, supported by Regulatory Authorities worldwide and were most recently replicated outside of a clinical study setting by an independent FDA assessment involving more than 134,000 Medicare patients.1-4
Boehringer Ingelheim will be hosting a media briefing during the ESC congress to present the new data, discuss how Pradaxa® is impacting patients in everyday clinical practice and give an update on the ongoing R&D programme including the progress of the investigational antidote idarucizumab. Medical media who are interested in attending the Boehringer Ingelheim briefing ‘Setting the Record Straight - Pradaxa® Protection Today and Tomorrow’ on Monday 1st September, 14.00-15.00 in the Industry Press Conference Room, should contact pradaxa@ogilvy.com
Contacts
Boehringer Ingelheim
Corporate Communications
Media + PR
Friederike Middeke
Phone: +49 6132 – 77 141 575
Fax: +49 6132 – 77 6601
Email: press@boehringer-ingelheim.com
Permalink: http://www.me-newswire.net/news/11903/en
keep it up
ReplyDeleteThe machines are running on PC. Just once introduce the product and machine will pursue the product and it will keep running as indicated by the order but you can click on http://www.cardiologyfellowship.net/weill-cornell-cardiology-fellowship-program/ for useful work. It isn't important to care for the machine. It will simply pursue the directions of the product.
ReplyDelete